دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Tuning up UK clinical trials
doi : 10.1016/S2665-9913(23)00102-9
Volume 5, Issue 5, May 2023, Page e239
Is it Autumn for colchicine and osteoarthritis?
Fiona E Watt a b c
Et tu, Brutinib? Demise of a kinase target in rheumatoid arthritis?
Peter C Taylor a
Reconciling immunotherapy and autoimmunity: not for the faint of heart
Carrie Ye a
Serious infections in patients with systemic lupus erythematosus: how can we prevent them?
Yann Nguyen a b, Nathalie Costedoat-Chalumeau a b
Post-COVID-19 condition in patients with autoimmune rheumatic diseases: the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study
doi : 10.1016/S2665-9913(23)00066-8
Volume 5, Issue 5, May 2023, Pages e247-e250
Correction to Lancet Rheumatol 2023; 5: e274–83
doi : 10.1016/S2665-9913(23)00103-0
Volume 5, Issue 5, May 2023, Page e251
Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial
Anna Døssing MD a, Prof Marius Henriksen PT a, Karen Ellegaard PhD a, Sabrina Mai Nielsen PhD c m, Prof Lisa K Stamp PhD f, Felix C Müller PhD d, Prof Margreet Kloppenburg MD g, Ida K Haugen PhD h, Prof Geraldine M McCarthy FRCPI i, Prof Philip G Conaghan PhD j, Louise Ulff-Møller Dahl MSc a, Prof Lene Terslev MD e, Prof Roy D Altman MD k †, Fabio Becce MD l, Elisabeth Ginnerup-Nielsen MHS a, Lene Jensen PT a, Prof Mikael Boesen MD b, Prof Robin Christensen MSc c m, Ulla Dal BA n, Prof Henning Bliddal DMSc a
Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study
doi : 10.1016/S2665-9913(23)00089-9
Volume 5, Issue 5, May 2023, Pages e263-e273
Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study
Kaitlin R McCarter MD a d, Taylor Wolfgang MD a b d, Senada Arabelovic DO a b d, Xiaosong Wang MSc a d, Kazuki Yoshida ScD a b d, Emily P Banasiak BA a b, Grace Qian BA&Sc a b, Emily N Kowalski BS a b, Kathleen M M Vanni BA a b, Nicole R LeBoeuf MD c d e, Elizabeth I Buchbinder MD a d e, Lydia Gedmintas MD a b d, Lindsey A MacFarlane MD a b d, Deepak A Rao MD a b d, Nancy A Shadick MD a b d, Prof Ellen M Gravallese MD a b d, Jeffrey A Sparks MD a b d
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study
doi : 10.1016/S2665-9913(23)00091-7
Volume 5, Issue 5, May 2023, Pages e284-e292
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?
Lindsay A N Crowe PhD a, Moeed Akbar PhD a, Robert-Jan de Vos MD b, Paul D Kirwan PhD c d, Prof Michael Kjaer MD e, Carles Pedret MD f, Prof Iain B McInnes FRCP a, Prof Stefan Siebert FRCP a, Prof Neal L Millar FRCSEd[Tr&Orth] a
